About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Current Update on the Abiraterone Expanded Access Trial

The latest from Jan Manarite of PCRI about the getting early access to Abiraterone for men with advanced prostate cancer and who have failed chemotherapy: Abiraterone expanded Access Trial Site Contact Info – 2/7/11 (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic 3. no brain [...]

The House is About to Cut Funding for Cancer Research & Prevention!

The House Appropriations Committee released revised subcommittee allocations yesterday for FY 2011. The new FY 2011 Labor-HHS-Education Subcommittee allocation is $157.02 billion, which is nearly $6.6 billion (4 percent) below the subcommittee’s FY10 allocation. The House is scheduled to vote on a FY11 appropriations bill during the week of February 14. Specific funding levels and [...]

Timely Use of Zoledronic Acid Provides Both Longer Hospital Free Survival and Increased Survival

A recent study conducted at the Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA by the Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA, evaluated the efficacy of the timely use of zoledronic acid (ZA) on clinical outcomes and health care utilization in men with bone-metastatic prostate [...]

More About Dosing Ketoconazole

There are two different dosage levels used for the administration of Ketoconazole (Keto), a commonly used 2nd line hormone deprivation drug used after the failure of the traditional drugs (Lupron, Zoladex etc.). Low dosage keto involves taking 200 mg three times a day (600 mg per day), while high dose keto uses 400 three times [...]

Ketoconazole – How To Take It So That It Works

Recently, I received two separate questions about both low dose ketoconazole (LDK) and high dose ketoconacole (HDK). For both of these men with castrate resistant advanced prostate cancer, their PSA scores continued to rise, despite their using keto. Even when taken properly, not all men experience a positive effect from the drug (a decline in [...]

Malecare Offers Free Access to CenterWatch’s Data Base of Clinical Trials for Prostate & Testicular Cancer

Malecare is proud to announce that we are now partnering with the Clinical Trials Resource Center. This partnership allows us to offer you, through our web site (www.malecare.org), CenterWatch’s data base of clinical trials that are being conducted both in the United States and internationally. CenterWatch is the leading publisher of information on clinical research [...]

Malecare’s New Clinical Trial Info Site

Malecare http://malecare.org/ announces it’s new, comprehensive and up-to-date clinical trials database and information pages. Click on the “Clinical Trials Center” button on the left side of our home page. Information on: Listing of Current Clinical Trials Listing of Studies at the National Institutes of Health FDA Drug Approvals …Oncology Research Centers and New Medical Therapies [...]

Malecare Clinical Trial Info Site

Malecare http://malecare.org/ announces it's new, comprehensive and up-to-date clinical trials database and information pages. Click on the "Clinical Trials Center" button on the left side of our home page. Information on: Listing of Current Clinical Trials Listing of Studies at the National Institutes of Health FDA Drug Approvals ...Oncology Research Centers and New Medical Therapies [...]

By |2017-10-19T10:53:20-04:00January 31st, 2011|Treatment News|0 Comments

One Years Cost To Treat One man with Advanced Prostate Cancer

Of interest is a recent advanced prostate cancer survivor's post the cost of his treatments in 2010. His accompanying comments were: Often on these boards we discuss the cost of treating prostate cancer. Below you will find the summation of my 2010 medical costs. These are 100% prostate cancer related as I am otherwise healthy. [...]

Go to Top